Search
Captopril
go.drugbank.com/drugs/DB01197ApprovedInvestigationalCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the r...
Sertraline
go.drugbank.com/drugs/DB01104ApprovedInvestigationalSertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in th...
Products: SERTRALINA MK 50 MG TABLETAS RECUBIERTASSLV319
go.drugbank.com/drugs/DB05077ExperimentalSLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.
Peginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigationalApproved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label]. … Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors.
Thiabendazole
go.drugbank.com/drugs/DB00730ApprovedVet approvedWithdrawn2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of P...
Sitimagene ceradenovec
go.drugbank.com/drugs/DB04907ExperimentalIt is being developed by Ark Therapeutics.
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalORG-34517 is currently under investigation by Organon for the treatment of depression.
Imlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigational[A225836,A225921] Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.
Osemozotan
go.drugbank.com/drugs/DB05339ExperimentalMN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationalIt promotes tumor cell survival by sequestering proapoptotic proteins and blocking the intrinsic mitochondrial apoptotic pathway.